Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 4/2020

01-11-2020 | Septicemia | Original Article

Predictors of in-hospital mortality in patients with left ventricular assist device

Authors: Karthik Gonuguntla, Shivaraj Patil, Richard Gregory Cowden, Manish Kumar, Chaitanya Rojulpote, Abhijit Bhattaru, John Glenn Tiu, Peter Robinson

Published in: Irish Journal of Medical Science (1971 -) | Issue 4/2020

Login to get access

Abstract

Background

A left ventricular assist device (LVAD) is used to support patients with end-stage heart failure.

Aims

To examine the role of comorbidities and complications in predicting in-hospital mortality since the introduction of continuous flow (CF)-LVAD.

Methods

The Nationwide Inpatient Sample was queried from 2010 to 2014 using International Classification of Disease-9 code for LVAD among patients 18 years or older. The sample consisted of 2,359 patients (mean age = 55 ± 13.7 years, 76.8% men, 59.3% Caucasian).

Results

Comparative analysis revealed mortality did not differ from 2010 to 2014 (p = 0.653). Increases in comorbidities of atrial fibrillation, acute kidney injury, mechanical ventilation, body mass index ≥ 25, cerebrovascular disease, and mild liver disease were evidenced over the 5-year period (p values ≤ 0.049). Multivariate analysis showed that significant predictors of mortality were comorbid hemodialysis (AOR = 7.62, 95% CI [4.78, 12.27]), cerebrovascular disease (AOR = 5.38, 95% CI [3.49, 8.26]), mechanical ventilation (AOR = 3.83, 95% CI [2.84, 5.18]), mild liver disease (AOR = 1.96, 95% CI [1.38, 2.76]), and acute kidney injury (AOR = 1.62, 95% CI [1.16, 2.28]). Predictive complications included disseminated intravascular coagulation (AOR = 6.41, 95% CI [2.79, 6.84]), sepsis (AOR = 4.37, 95% CI [2.79, 6.84]), septic shock (AOR = 3.9, 95% CI [2.11, 7.59]), and gastrointestinal bleed (AOR = 1.81, 95% CI [1.11, 2.93]).

Conclusions

CF-LVADs have not reduced mortality, possibly due to utilization in patients with comorbid conditions. Future trials are necessary for improved patient selection and reduced post-procedural complications.
Appendix
Available only for authorised users
Literature
11.
go back to reference Frazier O et al (2007) Initial clinical experience with the HeartMate® II axial-flow left ventricular assist device. Tex Heart Inst J 34:275PubMedPubMedCentral Frazier O et al (2007) Initial clinical experience with the HeartMate® II axial-flow left ventricular assist device. Tex Heart Inst J 34:275PubMedPubMedCentral
17.
go back to reference Wang, E.S., et al. (2019) Impact of preoperative specialty consults on hospitalist comanagement of hip fracture patients. Wang, E.S., et al. (2019) Impact of preoperative specialty consults on hospitalist comanagement of hip fracture patients.
Metadata
Title
Predictors of in-hospital mortality in patients with left ventricular assist device
Authors
Karthik Gonuguntla
Shivaraj Patil
Richard Gregory Cowden
Manish Kumar
Chaitanya Rojulpote
Abhijit Bhattaru
John Glenn Tiu
Peter Robinson
Publication date
01-11-2020
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 4/2020
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-020-02246-y

Other articles of this Issue 4/2020

Irish Journal of Medical Science (1971 -) 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.